• Patients with Helicobacter pylori infection

• Those intolerant to oral antibiotics

• Patients failing oral antibiotic therapy

• Patients with dysphagia

• High antibiotic resistance risk patients

Helicobacter pylori has a global infection rate of about 50%, causing gastritis, peptic ulcers, gastric adenocarcinoma, and lymphoma. Traditional oral antibiotic therapy requires high doses, multiple types, and a 2-week regimen with ~50% side effects and antibiotic resistance risk. MacKay Memorial Hospital developed the world's first Intraluminal Therapy for H. pylori Infection (ILTHPI), obtaining a U.S. patent in 2021. During gastroscopy, a single dose (with intragastric pH control, mucolytic irrigation, and antimicrobial agent) can simultaneously eradicate H. pylori within 8-10 minutes. The therapy is safe, fast, effective, with only 2.9% side effects, no liver/kidney damage, and avoids secondary antibiotic resistance. From 2018-2023, 538 patients received ILTHPI, with triple antibiotics and pH control achieving 84.6% success. Results published in J Gastroenterol Hepatol, J Clin Med, Microorganisms, Biomedicines.

• World-first endoscopic intraluminal therapy

• 8-10 min single-dose treatment

• Local administration avoids systemic effects

• No liver/kidney metabolism burden

• Avoids secondary antibiotic resistance

• 84.6% eradication with triple antibiotics + pH control

• 718 patients treated cumulatively

• 5 registered clinical trials (NCT)

• Treatment duration: 8-10 min

• Single-dose, one-time procedure

• First SCI publication on intraluminal therapy

• Triple antibiotics + pH control: 84.6%

• Dual antibiotics + pH + bismuth: 76.5%

• pH + dual antibiotics: 49.1%

• Side effect rate: 2.9% (vs oral 50%)

• No secondary antibiotic resistance

• Full safety monitoring (SBP, MAP, HR)

• Continuous oxygen saturation >90%

• No liver/kidney metabolism burden

• Local treatment avoids systemic effects

• All 718 cases completed successfully

• Overall patient satisfaction: 95%

• Patients recommend to relatives and friends

• Fast, safe treatment with minimal side effects

• Active patient feedback affirms clinical results

• 2019: World-first intraluminal therapy SCI paper

• 2021: U.S. patent granted

• 5+ SCI publications

• Taiwan Innovation Tech Expo Gold Medal

• World's only simultaneous diagnosis and eradication center

• Pioneers new paradigm for H. pylori treatment

• Significantly reduces antibiotic resistance

• Improves patient comfort and adherence

• Shortens treatment from 14 days to 10 minutes

• Provides new global treatment option